So many stocks have done so well that there's a lot of gain to shelter, and fewer stocks to sell for loses this year.
Perhaps, but late comers may have been burned in certain issues. It was noted recently that biotech had actually suffered a full 10% correction, even as other sectors remain aloft. Certain related sectors are getting worked over by Republican attempts to undo Obamacare. On my radar are SNFs, in particular, getting killed by the uncertainty. I am surprised there hasn't been more outcry from AARP regarding the backdoor attempts to tweak health care policy through the tax reform effort. In some ways, what they're attempting is more destructive than outright repeal. The Murray - Alexander bill is a mere bandaid for the tax reform induced arterial wound. Senators Murkowski and Collins have been fairly quiet, but I think they surely understand that. They must be getting tremendous party pressure. Johnson is amazing. Pass throughs aren't being treated well enough under this bill according to him. What planet is he on? I have a hard time believing he won't be turned back into a yes.
Anyway, there have been pullbacks in issues with decent mid and late stage programs with little regulatory risk, if maybe some commercial risk. Such as AKAO and PRTK, along with CARA (at these prices, worth it for the pruritus program alone). I have added to all three recently.
Cheers, Tuck |
